Skip to main content
Clinical Trials/NCT04393168
NCT04393168CompletedPhase 1

Proof-of-concept Interventional Study to Evaluate the Feasibility of the New Method, LymphMonitor 1.0, to Assess Lymphatic Function, Consisting of Indocyanine Green-based Lymphatic Specific Tracer. and a Custom Fluorescence Measuring Investigational Device LymphMeter 1.0.

Nicole Lindenblatt1 site in 1 country10 target enrollmentStarted: May 22, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
10
Locations
1
Primary Endpoint
Areas under the normalized clearance curves (AUCs)

Study Overview

Brief Summary

Lymphedema is the consequence of injured lymphatic system and is characterized by chronic, often disabling swelling of am affected body part, often arm or leg. In the western world secondary lymphedema arises most commonly after removal lymph nodes in an operation as a part of cancer treatment (for example from the armpits or the groin region), however it may also develop as a result of radiation, any other operation, infection or injury that destroys a part of lymphatic system. The disease often develops even years after the event. While there is no cure for lymphedema at present, early detection would ensure timely physiotherapy and application of compression garments that significantly slow down or stop the progression of the disease. However, presently used methods of that are used for diagnosis and evaluating the stage of the disease, are either invasive and expensive or inaccurate and can only be performed at specialized medical centres.

Therefore, we developed a simple, affordable and accurate technology, LymphMonitor 1.0 that can allow for testing how efficiently the lymphatic system is functioning. The test can be performed at the local medical centre or potentially even at home.

In this study, we investigate whether LymphMonitor 1.0 technology can distinguish between a healthy and a diseased lymphatic system (in lymphedema). This method may allow early diagnosis of lymphedema so that the development of the disease can be detected and prevented early enough. By participating in the study the lymphedema patients are making an important contribution to increasing the quality of life of lymphedema patients. In LymphMonitor 1.0 method method, a solution of a safe fluorescent dye, indocyanine green, is injected painlessly using tiny microneedles, MicronJet600TM, directly into the skin of the arm or leg. After injection, this dye is removed from the skin only through the lymphatic vessels. The intensity of the fluorescence signal corresponds to the amount of dye left in the skin. The decrease in the fluorescence signal after the injection is measured on the surface on the skin using a new device, LymphMeter 1.0. The faster the dye (and that fluorescence signal) disappears from the surface of the skin, the better the lymphatic system works. Therefore in the arm or leg affected by lymphedema the fluorescence signal will decrease much slower compared to the healthy one.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •informed consent as documented by signature
  • •females and males 18 - 75 years old,
  • •established (stage 2 or higher) unilateral secondary arm or leg lymphedema resulting from lymphadectonomy, radiation or any other surgical treatment, infection or injury.
  • •good general health status.

Exclusion Criteria

  • •critical illness (active cancer, renal failure, hepatic dysfunction)
  • •active infection
  • •blood vascular malformations or diseases
  • •scleroderma
  • •primary lymphedema
  • •patients who underwent any surgical procedures for treatment of lymphedema (e.g. lymphovenous anastomosis, liposuction, lymph node transfer).
  • •contraindications to use ICG (VERDYE), i.e.
  • •patients with hypersensitivity to ICG or to sodium iodide
  • •patients with hypersensitivity to iodine,
  • •patients with hyper-thyroidism, patients with autonomic thyroid adenomas
  • •patients in which the injection of VERDYE was poorly tolerated in the past it must not be used again, since severe anaphylactic reactions might occur.
  • •hypersensitivity to albumin or its excipients
  • •women, who are pregnant (pregnancy test will be performed in case of women who did not undergo menopause),
  • •women who are breast feeding ,
  • •enrolment of the investigator, his/her family members, employees and other dependent persons,
  • •known or suspected non-compliance, drug or alcohol abuse,
  • •inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • •participation in another study with investigational drug within the 30 days preceding and during the present study,
  • •previous enrolment into the current study.

Arms & Interventions

Patients with unilateral arm or leg lymphedema

Experimental

Intervention: Lymphatic clearance measurement (Combination Product)

Outcomes

Primary Outcomes

Areas under the normalized clearance curves (AUCs)

Time Frame: Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.

Areas under the normalized clearance curves (AUCs) in healthy and lymphedema limbs measured over 3 hours after injection. To obtain the clearance curve, the fluorescence intensity values at the injection sites in healthy and lymphedema extremities at pre-determined timepoints

Secondary Outcomes

  • other clearance parameters: clearance constant (k) and half-life of clearance (t1/2); (healthy versus diseased).(Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.)
  • dimensions of the injected dye depot measured by FluoBeam(Dimensions will be measured immediately after injection and 1.5 hours and 3 hours after injection.)
  • Correlation/no correlation of clearance parameters with the extent of the swelling (limb volume) in lymphedema patients.(3 hours)

Investigators

Sponsor
Nicole Lindenblatt
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Nicole Lindenblatt

Deputy Director of the Division of Plastic and Hand Surgery

University of Zurich

Study Sites (1)

Loading locations...

Similar Trials